Home » Stocks » SRDX

SurModics, Inc. (SRDX)

Stock Price: $43.98 USD -1.45 (-3.19%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 603.38M
Revenue (ttm) 94.86M
Net Income (ttm) 1.12M
Shares Out 13.55M
EPS (ttm) 0.08
PE Ratio 549.75
Forward PE 126.58
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $43.98
Previous Close $45.43
Change ($) -1.45
Change (%) -3.19%
Day's Open 44.98
Day's Range 43.15 - 46.36
Day's Volume 57,744
52-Week Range 22.46 - 48.72

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 3 days ago

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Surmodics--Surmodics Announces TRANSCEND Trial 12-Month Data to be Presented at LINC 2021 Virtual Event.

Zacks Investment Research - 1 month ago

SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?

Business Wire - 2 months ago

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Avess--Surmodics Avess™ AV Fistula DCB First-in-Human Study Presented at VIVA 2020; Study finds 100 percent target lesion patency at 30 days.

GuruFocus - 2 months ago

According to the GuruFocus All-in-One Screener as of Nov. 5, the following medical technology stocks are popular among gurus.

Other stocks mentioned: ANIP, SRGA, VNDA, PETS
Zacks Investment Research - 2 months ago

Surmodics (SRDX) registered revenue decline in each of its core units in the fourth quarter.

Seeking Alpha - 2 months ago

Surmodics, Inc.'s (SRDX) CEO Gary Maharaj on Q4 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

SurModics (SRDX) delivered earnings and revenue surprises of -1900.00% and 4.03%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 2 months ago

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Surmodics--Surmodics Reports Fourth Quarter Fiscal 2020 Results

Seeking Alpha - 2 months ago

Surmodics is in the early stages of an extended growth period in our view, with high conversion potential from their pipeline. The company has key differentiators within its medical devices an...

Zacks Investment Research - 2 months ago

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 2 months ago

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Surmodics--Surmodics, Inc. (Nasdaq: SRDX), to webcast Fourth quarter fiscal 2020 earnings in a conference call on November 4, 2020.

Zacks Investment Research - 3 months ago

NUVA vs. SRDX: Which Stock Is the Better Value Option?

Other stocks mentioned: NUVA
Zacks Investment Research - 3 months ago

The FDA clearance of Surmodics' (SRDX) Pounce Thrombus Retrieval System will bolster the current treatment of complex PAD.

Zacks Investment Research - 3 months ago

Here are three stocks from three sub-sectors from MedTech that have held their ground despite the pandemic-led market mayhem.

Other stocks mentioned: HCA, QGEN
Zacks Investment Research - 4 months ago

Investor confidence is high on Surmodics (SRDX) stock, thanks to solid prospects.

Zacks Investment Research - 4 months ago

SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 5 months ago

Surmodics (SRDX) registered revenue growth in each of its core units viz. In Vitro Diagnostics and Medical Device in Q3.

Seeking Alpha - 5 months ago

Surmodics, Inc. (SRDX) CEO Gary Maharaj on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

SurModics (SRDX) delivered earnings and revenue surprises of 110.00% and 8.36%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 5 months ago

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #FDAClearance--Surmodics receives FDA 510(k) clearance for Sublime™ Radial Access 0.014 RX PTA Dilatation Catheter.

Business Wire - 5 months ago

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Surmodics--Surmodics Reports Third Quarter Fiscal 2020 Results and will hold a webcast conference call at 4 pm CT.

Zacks Investment Research - 5 months ago

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 5 months ago

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Surmodics--Surmodics issues an earnings release after market closes and will host a webcast of fiscal 2020 third-quarter conference call on August 5 at ...

Zacks Investment Research - 5 months ago

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 6 months ago

Top Ranked Momentum Stocks to Buy for June 29th

Other stocks mentioned: BEN, SPWH, ZS
Zacks Investment Research - 6 months ago

Surmodics (SRDX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Zacks Investment Research - 6 months ago

Top Ranked Momentum Stocks to Buy for June 26th 2020

Other stocks mentioned: CMC, HEAR, RIO
Zacks Investment Research - 7 months ago

SurModics (SRDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Investment Research - 7 months ago

Surmodics' (SRDX) receipt of CE Mark for SurVeil DCB should boost the company's Medical Devices segment.

Zacks Investment Research - 7 months ago

SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 8 months ago

Surmodics (SRDX) registered growth in one of its core units, Invitro Diagnostics, in Q2.

Seeking Alpha - 8 months ago

Surmodics' (SRDX) CEO Gary Maharaj on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

SurModics (SRDX) delivered earnings and revenue surprises of 180.00% and 1.57%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 8 months ago

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 10 months ago

SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 11 months ago

Surmodics' (SRDX) fiscal first-quarter earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.

Seeking Alpha - 11 months ago

Surmodics, Inc. (SRDX) CEO Gary Maharaj on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

SurModics (SRDX) delivered earnings and revenue surprises of 266.67% and -0.89%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 11 months ago

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a conc...

Zacks Investment Research - 1 year ago

Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a conc...

Zacks Investment Research - 1 year ago

Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q4.

Seeking Alpha - 1 year ago

Surmodics, Inc. (SRDX) CEO Gary Maharaj on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

SurModics (SRDX) delivered earnings and revenue surprises of 5.71% and 8.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Medical Products Industry Outlook: Prospects Seem Promising

Other stocks mentioned: APHA, BLFS
Zacks Investment Research - 1 year ago

Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.

Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for September 26th

Other stocks mentioned: CROX, ELF, HTH
Zacks Investment Research - 1 year ago

SurModics (SRDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Investment Research - 1 year ago

Year to date, the performance on Wall Street is projecting a glorious picture with no end to the bull run in sight, at least this year.

Other stocks mentioned: BMY, GCO, HTH, ZUMZ
Zacks Investment Research - 1 year ago

SurModics (SRDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

About SRDX

Surmodics, together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to ... [Read more...]

Industry
Diagnostics & Research
IPO Date
Mar 4, 1998
CEO
Gary Maharaj
Employees
370
Stock Exchange
NASDAQ
Ticker Symbol
SRDX
Full Company Profile

Financial Performance

In 2020, SurModics's revenue was $94.86 million, a decrease of -5.21% compared to the previous year's $100.08 million. Earnings were $1.12 million, a decrease of -85.21%.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for SurModics stock is "Buy." The 12-month stock price forecast is 64.25, which is an increase of 46.09% from the latest price.

Price Target
$64.25
(46.09% upside)
Analyst Consensus: Buy